Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera

Blood

Volumn 128, Issue 2, 2016, Pages 265-276

  Casu, Carla ^a,b   Oikonomidou, Paraskevi Rea ^a,b   Chen, Huiyong ^c   Nandi, Vijay ^c   Ginzburg, Yelena ^c   Prasad, Princy ^d   Fleming, Robert E ^d   Shah, Yatrik M ^e   Valore, Erika V ^f   Nemeth, Elizabeta ^f   Ganz, Tomas ^f   MacDonald, Brian ^g   Rivella, Stefano ^a,b,h  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Merganser Biotech Inc   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; DEFERIPRONE; HEMOGLOBIN; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; HEPCIDIN; IRON; JANUS KINASE 2; MINIHEPCIDIN M004; MINIHEPCIDIN M009; STAT5 PROTEIN; UNCLASSIFIED DRUG; JAK2 PROTEIN, MOUSE; PEPTIDE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA THALASSEMIA; CHELATION THERAPY; CONTROLLED STUDY; DOSE RESPONSE; EC50; ERYTHROCYTE LIFESPAN; ERYTHROPOIESIS; GENE MUTATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; IRON BLOOD LEVEL; IRON OVERLOAD; IRON RESTRICTION; KUPFFER CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETICULOCYTE COUNT; SINGLE DRUG DOSE; SPLENOMEGALY; THALASSEMIA INTERMEDIA; TISSUE OXYGENATION; AMINO ACID SUBSTITUTION; ANIMAL; GENETICS; METABOLISM; MISSENSE MUTATION; MUTANT MOUSE STRAIN;

AMINO ACID SUBSTITUTION; ANIMALS; BETA-THALASSEMIA; ERYTHROPOIESIS; HEPCIDINS; JANUS KINASE 2; MICE; MICE, MUTANT STRAINS; MUTATION, MISSENSE; PEPTIDES; POLYCYTHEMIA VERA;

EID: 84978370086     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-676742     Document Type: Article

References (28)

1. Rivella S. β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica. 2015;100(4):418-430.
2. Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest. 2013;123(4):1531-1541.
3. Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Invest. 2010;120(12):4466-4477.
4. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013;98(6):833-844.
5. Anderson ER, Taylor M, Xue X, et al. Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia. Proc Natl Acad Sci USA. 2013;110(50):E4922-E4930.
6. Adamsky K, Weizer O, Amariglio N, et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol. 2004;124(1):123-124.
7. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684.
8. Parrow NL, Gardenghi S, Ramos P, et al. Decreased hepcidin expression in murine β-thalassemia is associated with suppression of Bmp/Smad signaling. Blood. 2012;119(13):3187-3189.
9. Anderson SA, Nizzi CP, Chang YI, et al. The IRP1-HIF-2α axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption. Cell Metab. 2013;17(2):282-290.
10. Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle. 2008;7(1):28-32.
11. Mullally A, Lane SW, Ball B, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17(6):584-596.
12. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
13. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790.
14. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
15. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
16. Marchioli R, Finazzi G, Specchia G, et al; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
17. Ramos E, Ruchala P, Goodnough JB, et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood. 2012;120(18):3829-3836.
18. Preza GC, Ruchala P, Pinon R, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest. 2011;121(12):4880-4888.
19. Kautz L, Jung G, Du X, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood. 2015;126(17):2031-2037.
20. Libani IV, Guy EC, Melchiori L, et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood. 2008;112(3):875-885.
21. Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007;109(11):5027-5035.
22. Ramos P, Melchiori L, Gardenghi S, et al. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models. Ann N Y Acad Sci. 2010;1202:24-30.
23. Casu C, Aghajan M, Oikonomidou PR, Guo S, Monia BP, Rivella S. Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. Haematologica. 2016;101(1):e8-e11.
24. Melchiori L, Gardenghi S, Rivella S. beta-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload. Adv Hematol. 2010;2010:938640.
25. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001;98(12):3261-3273.
26. Ramos P, Casu C, Gardenghi S, et al. Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nat Med. 2013;19(4):437-445.
27. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92(5):583-588.
28. Schmidt PJ, Racie T, Westerman M, Fitzgerald K, Butler JS, Fleming MD. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia. Am J Hematol. 2015; 90(4):310-313.